von Willebrand factor A1 domain (vWF-A1) (vWF-A1)

The von Willebrand factor (vWF) A1 domain is a specialized structural region within the vWF glycoprotein that mediates the critical first step of hemostasis: platelet adhesion to the vascular wall (UniProt P04275). Under high shear stress, such as in narrowed arteries or microvessels, the A1 domain undergoes a conformational change that allows it to bind to the platelet glycoprotein Ib-IX-V (GPIb) receptor complex (PubMed: 29320647). This interaction is essential for primary hemostasis but can become pathological in conditions like acquired thrombotic thrombocytopenic purpura (aTTP), where ultra-large vWF multimers cause widespread microvascular thrombosis (NIH: NBK537272). Pharmacological inhibition of the A1 domain, exemplified by the nanobody caplacizumab, prevents this interaction, thereby reducing platelet consumption and protecting against organ ischemia (FDA: Cablivi Label). Beyond TTP, the A1 domain is a target of interest for preventing arterial thrombosis and stroke without the significant bleeding risks associated with traditional antiplatelet agents (PubMed: 30625057). The domain also interacts with other ligands such as collagen type VI and heparin, which may influence its role in vascular biology (UniProt P04275). Therapeutic strategies targeting this domain focus on blocking the A1-GPIb axis to manage acute thrombotic episodes (PubMed: 31166319).

Other names

vWF A1 domainVWF-A1von Willebrand factor domain A1

The mechanism of action involves the targeted inhibition of the von Willebrand factor A1 domain, specifically blocking its interaction with the platelet glycoprotein Ib (GPIb) receptor. This blockade prevents the adhesion of platelets to ultra-large vWF multimers and the subendothelial matrix under high shear stress, thereby inhibiting the formation of microvascular thrombi (FDA: Cablivi Label; PubMed: 29320647).